Movatterモバイル変換


[0]ホーム

URL:


Journal Logo

Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.

Export to

Original Contributions: PDF Only

Prognostic factors in Stage T2NO rectal cancer

Do all patients require postoperative pelvic irradiation and chemotherapy?

Willett, Christopher G. M.D.1; Badizadegan, Kamran M.D.2; Ancukiewicz, Marek Ph.D.1; Shellito, Paul C. M.D.3

Author Information

3the Department of Surgery

Massachusetts General Hospital

Boston

Massachusetts

2the Department of Pathology

Children's Hospital and Brigham and Women's Hospital

Boston

Massachusetts

1Radiation Oncology

Massachusetts General Hospital

Fruit Street

02114

Boston

Massachusetts

Diseases of the Colon & Rectum42(2):p 167-173, February 1999. |DOI:10.1007/BF02237122

Abstract

PURPOSE: 

To further define the indications for postoperative pelvic irradiation and chemotherapy, an analysis of the influence of extent of tumor invasion into perirectal fat, lymphatic or venous vessel invasion, and tumor grade on the clinical course of patients with Stage T2NO rectal cancer undergoing surgery was undertaken.

METHODS: 

From 1968 to 1985, 117 patients with Stage T3NO rectal cancer underwent resection with curative intent. No patient received neoadjuvant or adjuvant irradiation or chemotherapy. Surgical specimens were assessed for maximum depth of tumor invasion into perirectal fat, lymphatic or venous involvement, and tumor grade. After surgery the clinical course of these patients was assessed for local control, distant metastases, and survival rate.

RESULTS: 

For 25 patients with tumors exhibiting favorable histologic features (well-differentiated or moderately well-differentiated carcinomas invading less than 2 mm into perirectal fat, without lymphatic or venous vessel involvement), the ten-year actuarial rates of local control and recurrence-free survival were 95 and 87 percent, respectively. In contrast, the ten-year actuarial rates of local control and recurrence-free survival were inferior (71 and 55 percent, respectively) for 88 patients with tumors exhibiting moderate to deep perirectal fat invasion, vessel involvement, or poor differentiation.

CONCLUSIONS: 

In the design of future trials of rectal cancer, selection of patients with rectal cancer for postoperative adjuvant therapy should be based not only on stage, but also on depth of invasion into the perirectal fat, vessel involvement, tumor grade, and integrity of the radial resection margin. For subsets of patients with Stage T3NO rectal cancer, there may be little benefit to adjuvant therapy after surgery.

© The ASCRS 1999

You can read the full text of this article if you:

Log InAccess through Ovid
Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.


[8]ページ先頭

©2009-2025 Movatter.jp